In this meta-analysis, the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be tolerable and resolved within 48 hours. However, future studies need to more actively evaluate the appropriate management of adverse effects.

These findings suggest that a single administration of psilocybin is safe with regard to acute psychological and physical harm in healthy participants in a controlled research setting.

These findings highlight the importance of the therapeutic relationship in PAT. Future research should explore therapist and participant characteristics which maximize the therapeutic alliance and evaluate its relationship to treatment outcomes.

In conclusion, our synaptic protein findings suggest that PME (mushroom extract) has a more potent and prolonged effect on synaptic plasticity than PSIL (synthesized psilocybin).

"The obvious gap in the palliative care toolbox is a tool for the relief of nonphysical suffering, and psilocybin is that tool." "It's really essential that everyone in patients' rights, hospice and the palliative care movement stand up and insist that it be available sooner rather than later."

This report is from a non-medical psychedelic retreat centre documenting participant responses to a series of surveys on continuing benefits for depression and anxiety symptoms.

This is the first time psilocybin has been investigated for treatment of generalised anxiety disorder, and the reduction in HAM-A scores we have observed are far greater those reported from trials on established medicines for treatment of anxiety.

The social acceptability of psilocybin-assisted therapy for existential distress at the end of life is rather high in Canada. These findings may contribute to efforts to mobilise resources and improve access to this emerging therapy in palliative and end of life care settings.

A European consortium of 19 partners has been awarded €6,5 million by the European Union’s Horizon Europe programme to study psilocybin to treat psychological distress in people with progressive incurable illnesses requiring palliative care.

The findings in this open-label nonrandomized controlled trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.

The psilocybin arm showed a lower likelihood of symptom worsening versus waitlist, and no difference in the likelihood of symptom worsening versus escitalopram.

I’ve had a chance to sample numerous legacy mushroom market products, ranging from psilocybin-infused chocolate to jerky to gummies to honey to water-soluble drink packets to liquor to marshmallows and more. In the spirit of harm reduction, education, and providing some context for the elusive and nebulous legacy mushroom market, I’ll review a few of the many branded products now floating around.

These results establish a well-validated regimen for further experiments probing the effects of repeated low doses of psilocybin. Results further substantiate anecdotal reports of the benefits of psilocybin microdosing as a therapeutic intervention, while pointing to a possible physiological mechanism.

Results from this study, the largest prospective survey of naturalistic psilocybin use to date, support the potential for psilocybin to produce lasting improvements in mental health symptoms and general wellbeing.

Findings suggest co-use of MDMA with psilocybin/LSD may buffer against some aspects of challenging experiences and enhance certain positive experiences.

Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events.

This pilot study demonstrated the safety, feasibility, and possible efficacy of psilocybin-assisted group therapy for cancer patients dealing with depressive symptoms. Based on demonstrated efficacy and significant reductions in therapist time, future investigations with the group therapy model are warranted.

We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin.